Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Dec;266(6):952-961.
doi: 10.1097/SLA.0000000000002286.

Beta-blockers and Traumatic Brain Injury: A Systematic Review, Meta-analysis, and Eastern Association for the Surgery of Trauma Guideline

Affiliations
Meta-Analysis

Beta-blockers and Traumatic Brain Injury: A Systematic Review, Meta-analysis, and Eastern Association for the Surgery of Trauma Guideline

Aziz S Alali et al. Ann Surg. 2017 Dec.

Abstract

Objective: To determine if beta-(β)-blockers improve outcomes after acute traumatic brain injury (TBI).

Background: There have been no new inpatient pharmacologic therapies to improve TBI outcomes in a half-century. Treatment of TBI patients with β-blockers offers a potentially beneficial approach.

Methods: Using MEDLINE, EMBASE, and CENTRAL databases, eligible articles for our systematic review and meta-analysis (PROSPERO CRD42016048547) included adult (age ≥ 16 years) blunt trauma patients admitted with TBI. The exposure of interest was β-blocker administration initiated during the hospitalization. Outcomes were mortality, functional measures, quality of life, cardiopulmonary morbidity (e.g., hypotension, bradycardia, bronchospasm, and/or congestive heart failure). Data were analyzed using a random-effects model, and represented by pooled odds ratio (OR) with 95% confidence intervals (CI) and statistical heterogeneity (I).

Results: Data were extracted from 9 included studies encompassing 2005 unique TBI patients with β-blocker treatment and 6240 unique controls. Exposure to β-blockers after TBI was associated with a reduction of in-hospital mortality (pooled OR 0.39, 95% CI: 0.27-0.56; I = 65%, P < 0.00001). None of the included studies examined functional outcome or quality of life measures, and cardiopulmonary adverse events were rarely reported. No clear evidence of reporting bias was identified.

Conclusions: In adults with acute TBI, observational studies reveal a significant mortality advantage with β-blockers; however, quality of evidence is very low. We conditionally recommend the use of in-hospital β-blockers. However, we recommend further high-quality trials to answer questions about the mechanisms of action, effectiveness on subgroups, dose-response, length of therapy, functional outcome, and quality of life after β-blocker use for TBI.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST WITH OTHER SOURCES OF SUPPORT:

Dr. Patel has been or is supported by the Vanderbilt Institute for Clinical and Translational Research awards (VR1584, VR5351, VR9276, VR12073) via CTSA grant UL1TR000011 (NCRR/NCATS/NIH), a 2013 EAST Trauma Foundation Research Scholarship, and speaker fees from Pfizer. Drs. Haut and Patel have served on the EAST Guidelines Section and Board of Directors. Dr. Haut is the primary investigator of a AHRQ grant (R01HS024547) of a PCORI contract (CE-12–11–4489). Dr. Haut receives book royalties from Lippincott, Williams, Wilkins (“Avoiding Common ICU Errors”), consultant and speaker fees from VHA/Vizient IMPERATIV® Advantage Performance Improvement Collaborative, and consultant and speaker fees for the Illinois Surgical Quality Improvement Collaborative. Dr. Haut was the paid author of a paper commissioned by the National Academies of Medicine.

Figures

Figure 1
Figure 1
PRISMA flow diagram for systematic review phases of Beta-Blockers after traumatic brain injury
Figure 2
Figure 2
Forest plot of Beta-blocker exposure after acute traumatic brain injury versus no exposure with in-hospital mortality outcome
Figure 3
Figure 3
Practice management guideline for Beta-Blockers after traumatic brain injury *Provided that common ICU complications of hypotension (i.e., usually defined as systolic blood pressure<90mmHg) and symptomatic bradycardia (is, usually defined as heart rate<50 with symptoms) are avoided

References

    1. Menon DK, Zahed C. Prediction of outcome in severe traumatic brain injury. Current Opinion in Critical Care. 2009 Oct;15(5):437–41. - PubMed
    1. Heffernan DS, Inaba K, Arbabi S, Cotton BA. Sympathetic Hyperactivity After Traumatic Brain Injury and the Role of Beta-Blocker Therapy. The Journal of Trauma: Injury, Infection, and Critical Care. 2010 Dec;69(6):1602–9. - PubMed
    1. Tran TY, Dunne IE, German JW. Beta blockers exposure and traumatic brain injury: a literature review. Neurosurgical Focus. 2008 Oct;25(4):E8. - PubMed
    1. Ley EJ, Berry C, Mirocha J, Salim A. Mortality is Reduced for Heart Rate 80 to 89 After Traumatic Brain Injury. Journal of Surgical Research. 2010 Sep;163(1):142–5. - PubMed
    1. Radosevich JJ, Patanwala AE, Erstad BL. Emerging pharmacological agents to improve survival from traumatic brain injury. Brain Inj. 2013 Nov 11;27(13–14):1492–9. - PubMed

Substances